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Identiﬁcation of an HLA-A3-Restricted Cytotoxic T Lymphocyte
(CTL) Epitope from ML-IAP
To the Editor:
ML-IAP (also named livin) is a critical cellular factor since
increased expression levels confer resistance to apoptotic
stimuli, thereby contributing to the pathogenesis and
progression of melanoma (Kasof and Gomes, 2001;
Nachmias et al, 2003). Thus, the majority of melanoma cell
lines express high levels of ML-IAP in contrast to primary
melanocytes. Additionally, Nachmias et al, recently detected
the livin protein in ten of 27 melanoma cultures from primary
melanoma patients. Furthermore, they demonstrated the
significance of livin in the drug-resistance phenotype
characterizing this disease and showed a clinical correlation
between livin expression and chemotherapeutic response.
Thus, the attractiveness of using ML-IAP for vaccination
purposes is based on the fact that downregulation or loss of
expression of this protein as some form of immune escape
would impair sustained tumor growth. In this regard, we
recently demonstrated that a large proportion of melanoma
patients host a spontaneous T cell response specifically
against ML-IAP-derived peptides presented in the context
of the HLA-A2 antigen (Andersen et al, 2003).
One of the HLA-A2 antigen-restricted epitopes identified
from ML-IAP was the deca-mer peptide ML-IAP245–254
(RLQEERTCKV). Interestingly, the analog nona-mer peptide
ML-IAP245–253 (RLQEERTCK) comprises the perfect anchor
motif for the HLA-A3 antigen (leucin at position 2 and lysine
at C-terminal position) (Kubo et al, 1994). Since the deca-
mer peptide is presented by melanoma cells in the context
of the HLA-A2 antigen, it can be presumed that the nona-
mer peptide likewise is generated by the antigen-proces-
sing machinery and subsequently is presented in the
context of HLA-A3 antigen. To investigate this, we analyzed
peripheral blood lymphocyte (PBL) from 14 HLA-A3
antigen-positive melanoma patients for spontaneous im-
mune responses by means of ELISPOTagainst this peptide.
To this end, five of the melanoma patients hosted an
immune response of more than 200 ML-IAP245–253
(RLQEERTCK) specific T cells per 105 CD8þ cells (Fig 1).
Thus, spontaneous immune responses against this epitope
are present in around one-third of the HLA-A3 antigen-
positive patients. In the present study, we have only
examined late-stage melanoma patients only treated by
surgery. Thus, it is not possible to conclude if the presence
of a CTL immune response against ML-IAP correlates with
certain characteristics of the disease.
The characterization of multiple ML-IAP epitopes with
different HLA class I restriction elements broadens the
clinical potential of this target antigen in two important
ways:
On the one hand, it increases the number of patients
eligible for immunotherapy based on ML-IAP derived
peptides, since even though the HLA-A2 antigen is one of
the most frequently expressed HLA class I molecules, it is
still only expressed in around 50% of melanoma patients.
The HLA-A3 antigen is expressed by 30% of patients
(Kessler et al, 2003). Co-expression is found in around 10%
of patients. Thus, approximately 70% of the patients can be
vaccinated with the ML-IAP epitopes identified thus far. This
percentage of patients would be further increased by the
identification of additional ML-IAP peptide epitopes that is
restricted to other common HLA class I alleles such as HLA-
A1, HLA-A11, and HLA-A24 antigens. The combination of
these would encompass 490% of the Caucasian popula-
tion (Vonderheide et al, 2001).
Figure1
T cell response against the peptide ML-IAP245–253 (RLQEERTCK).
PBL from 14 melanoma patients were analyzed by means of ELISPOT
as described (Andersen et al, 2003). T lymphocytes were stimulated
once with peptide before being plated in triplicates either without or
with peptide. The average number of peptide-specific cells (after
subtraction of spots without added peptide) was calculated for each
patient as the number of spot forming cells per 105 CD8þ cells after
subtraction of the number of background spots formed without
addition of peptide using the ImmunoSpot Series 2.0 Analyzer (CTL
Analyzers, LLC, Cleveland, Ohio).
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One the other hand, the collective targeting of several
restriction elements is likely to decrease the risk of immune
escape by class I HLA-allele loss. Loss of a single class I
HLA allele is a significant component of MHC alterations
described in cancer cells, whereas total loss of class I HLA
expression is a rather infrequent event (Garrido et al, 1997;
Koopman et al, 2000; Marincola et al, 2000). Although the
percentage of patients expressing both HLA-A2 and HLA-
A3 antigens is only 10%, the identification of epitopes for
other class I HLA alleles will increase this percentage of
patients with allelic overlap.
Over the past decade, numerous clinical trials have
shown the feasibility of peptide specific vaccination to
induce anti-tumor T cell responses in cancer patients. The
clinical course of the patients, however, was in most cases
not improved. This discrepancy has in numerous cases
been explained by immune escape mechanisms of the
tumor cells (Campoli et al, 2002). The attractiveness of using
ML-IAP for vaccination purposes relies on the fact that
downregulation or loss of expression of this protein as a
means of immune escape would impair sustained tumor
growth. The availability of multiple ML-IAP epitopes
presented by different HLA class I restriction elements
further reduces the risk of immune escape and thereby
therapeutic failures. It should be mentioned, however, that
use of the gene products of one HLA class I locus as
restricting elements does not counteract downregulation
of the gene products of one locus as an escape mechan-
ism. The use of peptides using gene products of different
HLA class I loci as restricting elements may be more
effective.
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